So should Denali Therapeutics (NASDAQ:DNLI) shareholders be worried about its cash burn? For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each ...

SALT LAKE CITY — Denali Therapeutics is advancing the fight against neurodegenerative diseases thanks to pioneering work in methods to carry medicines across the blood-brain barrier, a critical ...

DNL310 received Breakthrough Therapy Designation; BLA filing for Hunter syndrome is anticipated in early 2025. Denali's $1.28 billion cash runway supports expansion efforts, aiming for ...

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) gapped down prior to trading on Tuesday after JPMorgan Chase & Co. lowered their price target on the stock from $28.00 to $24.00.

You can reach Allison on Signal at AllisonDeAngelis.01. A new company is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug candidates and raising ...

Fintel reports that on December 16, 2024, Stifel upgraded their outlook for Denali Therapeutics (NasdaqGS:DNLI) from Hold to Buy. Analyst Price Forecast Suggests 86.85% Upside As of December 3 ...

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2024, and provided ...

Denali Therapeutics announces its Phase 2 study of oditrasertib was discontinued. Denali's strategic partner says the study failed to meet the primary and key secondary endpoints. Discover how ...

Denali Therapeutics is headquartered in northern California. The company has developed a broad portfolio of product candidates that are engineered to cross the blood-brain barrier. They are ...

Denali Therapeutics Inc. (NASDAQ:DNLI) is advancing a drug by the name of DNL-310 [tividenofusp alfa] for the treatment of patients with MSP II [Hunter Syndrome]. It had been able to report ...